Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Hard Copy Enterprisewide Thought Leader Insight & Analysis: Alzheimer's Disease Medpredict, Jan 2008   Description     Table of Contents     Products Mentioned        Enquire before Buying    Send to a Friend   This report focuses on a variety of clinical approaches and diagnostics targeting either cognition or disease progression in Alzheimer’s disease. The report, #14 in the series, is based on seven interviews conducted with a cohort of national US peer-recognized AD experts. As 2008 begins the publisher’s Panelists were asked to review major developments this past year and to forecast the changes they expect to see in the Alzheimer’s competitive landscape in 2008. Each Panelist offers his perspective on those agents and mechanisms that have the strongest data supporting them, and comments on those where the excitement extends beyond the clinical evidence. These include acetylcholinesterase (butyrylcholinesterase) inhibitors, NMDA, M1, 5-HT, alpha-7 nicotinic acetylcholine agonists, active and passive immunotherapy, ?-secretase and ß-secretase inhibitors, insulin related mechanisms (IDE, RAGE), plasminogen activator inhibitor-1, anti-TNF, GSK3 and more. Given the size of the patient population and the lack of approved therapeutics that provide long-term disease control it is no surprise how many competitors are trying to commercialize drugs for this market. This in addition to the drugs highlighted as most interesting by the Panel the publisher offers in this report a program guide of new compounds, reflecting the many “shots on goal”. The publisher does this with the caveat that just because they name them doesn’t mean that they endorse them. The AD field is strewn with the bones of much hyped new chemical entities that did not stand up to closer scrutiny. But, they do provide a starting point for future Panel discussions. Customers who bought this item also bought Thought Leader Insight & Analysis: Alzheimers Disease Pharmaceutical Opinion Leader Management Thought Leader Insight & Analysis: Anxiety & Depression Leader Energy Services Ltd. Company Profile GSK-Smithkline Beecham: Competitive Benchmarking Report Thought Leader Compensation: Establishing Fair-Market Value Procedures The Executive�s Guide to the World�s Leading Pharmaceutical Companies 2007 Asthma: Opinion Leader Forum - Experts Views and Perspectives on Diagnosis, Treatment, Products, Performance and Closing the Need Gap

		Top of page

All rights reserved. � Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster